Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.61) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.10, Zacks reports. The firm had revenue of $92.13 million during the quarter, compared to the consensus estimate of $85.56 million. Rhythm Pharmaceuticals had a negative net margin of 85.59% and a negative return on equity of 159.87%. The company's quarterly revenue was up 79.6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.82) earnings per share.
Here are the key takeaways from Rhythm Pharmaceuticals' conference call:
- Strong U.S. acquired hypothalamic obesity launch: Q3 global IMCIVREE revenue rose 29% sequentially to $92.1 million, with U.S. revenue of $67.5 million. Rhythm reported more than 700 acquired HO patient start forms, over 500 prescribers, and continued demand growth entering Q4.
- Encouraging market access: Approximately 60% of Medicaid-covered lives and 75% of commercial-covered lives were covered by acquired HO policies at quarter-end, while more than 80% of reimbursement approvals were obtained within 60 days of receiving a start form.
- International expansion is underway: IMCIVREE launched in Japan on October 14 at a price of approximately $2,200 per vial, with more than 1,000 potentially eligible patients identified. Rhythm expects Japan to become its second-largest market, although two-week prescription limits may constrain first-year revenue; European launches are expected to begin in 2027.
- Pipeline expansion: Rhythm plans to initiate a phase III bivamelagon study in hypothalamic obesity in early 2027 and pursue a six-month phase III Prader-Willi syndrome study focused on hyperphagia. Management also expects to develop next-generation MC4R therapies and potential combination approaches.
- Higher financing obligations: Rhythm amended its LG Chem agreement to reduce potential royalties to a 1% flat rate, but committed to $350 million in payments over four years and took an initial $250 million term loan at SOFR plus 4.6%. The company ended Q3 with about $321 million in cash and investments, excluding these transaction-related cash flows.
Rhythm Pharmaceuticals Price Performance
Shares of NASDAQ:RYTM traded down $9.55 during mid-day trading on Tuesday, reaching $83.89. 2,764,239 shares of the company traded hands, compared to its average volume of 760,835. The company's 50 day moving average price is $96.85 and its 200-day moving average price is $97.29. The firm has a market cap of $5.75 billion, a PE ratio of -26.75 and a beta of 2.01. Rhythm Pharmaceuticals has a 52 week low of $74.50 and a 52 week high of $122.20.
Insider Activity at Rhythm Pharmaceuticals
In other Rhythm Pharmaceuticals news, insider Alastair Garfield sold 7,763 shares of the company's stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $117.57, for a total value of $912,695.91. Following the completion of the transaction, the insider directly owned 2,295 shares in the company, valued at $269,823.15. This represents a 77.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO David P. Meeker sold 50,000 shares of the stock in a transaction on Monday, September 14th. The stock was sold at an average price of $102.67, for a total transaction of $5,133,500.00. Following the completion of the sale, the chief executive officer directly owned 239,258 shares of the company's stock, valued at approximately $24,564,618.86. This trade represents a 17.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 258,450 shares of company stock worth $28,796,497 in the last 90 days. Insiders own 5.90% of the company's stock.
Analyst Ratings Changes
A number of brokerages recently issued reports on RYTM. Citigroup restated a "market outperform" rating on shares of Rhythm Pharmaceuticals in a report on Wednesday, August 5th. Leerink Partners started coverage on Rhythm Pharmaceuticals in a research report on Monday, September 14th. They issued an "outperform" rating and a $133.00 price objective on the stock. William Blair started coverage on Rhythm Pharmaceuticals in a research note on Friday, October 16th. They set an "outperform" rating on the stock. Citizens Jmp upped their target price on Rhythm Pharmaceuticals from $155.00 to $160.00 and gave the company a "market outperform" rating in a report on Wednesday, August 5th. Finally, HC Wainwright raised their price target on Rhythm Pharmaceuticals from $105.00 to $130.00 and gave the stock a "buy" rating in a research note on Monday, October 12th. Eighteen analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $142.50.
View Our Latest Stock Analysis on RYTM
About Rhythm Pharmaceuticals
(
Get Free Report)
Rhythm Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare genetic diseases of obesity and related metabolic disorders. The company's work is based on the melanocortin-4 receptor (MC4R) pathway, which plays an important role in regulating hunger and energy balance.
Rhythm's principal product is IMCIVREE (setmelanotide), a targeted therapy designed to restore impaired MC4R pathway signaling. In the United States, IMCIVREE is approved for chronic weight management in adults and children at least 6 years old with obesity caused by certain genetic deficiencies, including POMC, PCSK1, or LEPR deficiency, as well as Bardet-Biedl syndrome.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Rhythm Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rhythm Pharmaceuticals wasn't on the list.
While Rhythm Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.